Long term adjuvant endocrine therapy and risk of CVD in female breast cancer survivors

U.K. researchers examined whether taking tamoxifen or aromatase inhibitors influenced cardiovascular disease (CVD) outcomes in women with a history of non-metastatic breast cancer. The investigation took the shape of a systematic review and meta-analysis, with evidence from 26 relevant studies published up to June 2018.

U.K. researchers examined whether taking tamoxifen or aromatase inhibitors influenced cardiovascular disease (CVD) outcomes in women with a history of non-metastatic breast cancer. The investigation took the shape of a systematic review and meta-analysis, with evidence from 26 relevant studies published up to June 2018. The findings suggested an association between tamoxifen, vs. aromatase inhibitors or no endocrine therapy, and venous thromboembolism. Aromatase inhibitor use, meanwhile, was correlated with myocardial infarction and angina—although that might be attributed in part to tamoxifen's protective effect on those two outcomes. The data was limited and inconsistent for the remaining CVD endpoints, including stroke, heart failure, arrhythmia, and peripheral vascular disease. The review authors conclude that patient risk of venous or arterial vascular disease should help inform choice of tamoxifen or aromatase inhibitor, although effectiveness against breast cancer recurrence will serve as primary deciding factor.